Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

An Anionic Residue at Position 564 Is Important for Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor

Shinji Kosugi, Toru Mori and Andrew Shenker
Molecular Pharmacology May 1998, 53 (5) 894-901;
Shinji Kosugi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toru Mori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Shenker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Gonadotropin-independent, male-limited precocious puberty is caused by a variety of mutations in the lutropin/choriogonadotropin receptor (LHR) that produce constitutive receptor activation. Two of these mutations encode replacement of conserved aspartate residues at positions 564 and 578 with glycine. We previously used site-directed mutagenesis to study the functional role of the Asp578 side chain in transmembrane helix 6, and concluded that it is its ability to serve as a properly positioned interhelical hydrogen bond acceptor, rather than its negative charge, that is important for stabilizing the inactive state of the LHR. We now report the effects of substituting seven different amino acids for the Asp564 residue located at the carboxyl terminus of the third intracellular loop. Glycine, alanine, valine, leucine, phenylalanine, and asparagine produced constitutive activation in a COS-7 cell expression system (3–5-fold increase in basal cAMP), but glutamate did not, indicating that a negative charge at position 564 may be important for maintaining the inactive LHR conformation. Characterization of double-mutant receptors showed that certain substitutions at Asp564 and Asp578 have a cumulative effect on basal receptor activity, perhaps because they mimic different aspects of the activation process normally triggered by hormone binding.

Footnotes

  • Send reprint requests to: Dr. S. Kosugi, Department of Laboratory Medicine, Kyoto University School of Medicine, Room 223, First Clinical Research Building, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail:kosugi{at}kuhp.kyoto-u.ac.jp or Dr. A. Shenker, Children’s Memorial Hospital, Box 225, 2300 Children’s Plaza, Chicago, IL 60614. E-mail: ashenker{at}nwu.edu

  • This work was in part supported by grants-in-aid from the Japanese Ministry of Education (Nos. 0644128, 06671024, 07671129, 07557353, and 08671152), Mochida Foundation for Medical and Pharmaceutical Research, Kowa Foundation for Life Science, Shimizu Foundation for Immunology Research, Kyoto University Foundation, Kurozumi Foundation, Inamori Foundation, Fujiwara Foundation, Clinical Pathology Research Foundation of Japan, and SRF for Biomedical Research (all to S.K.)

  • Abbreviations:
    LHR
    lutropin/choriogonadotropin receptor
    GPCR
    G protein-coupled receptor
    TM
    transmembrane helix
    i3
    third intracellular loop
    WT
    wild-type
    hCG
    human chorionic gonadotropin
    AR
    adrenergic receptor
    IP
    inositol phosphate
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    • Received August 28, 1997.
    • Accepted February 2, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 53 (5)
Molecular Pharmacology
Vol. 53, Issue 5
1 May 1998
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An Anionic Residue at Position 564 Is Important for Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

An Anionic Residue at Position 564 Is Important for Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor

Shinji Kosugi, Toru Mori and Andrew Shenker
Molecular Pharmacology May 1, 1998, 53 (5) 894-901;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

An Anionic Residue at Position 564 Is Important for Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor

Shinji Kosugi, Toru Mori and Andrew Shenker
Molecular Pharmacology May 1, 1998, 53 (5) 894-901;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Nelfinavir and PXR
  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics